Novo Nordisk Reduces U.S. Obesity Education Team Amid Cost-Cutting Measures

September 19, 2025 - 04:46

VIENNA - Novo Nordisk, the manufacturer of the weight-loss drug Wegovy, has reportedly downsized its U.S. sales team dedicated to obesity and diabetes education for healthcare providers. This move, confirmed by two sources familiar with the situation and recent LinkedIn posts, indicates the company's strategy to streamline operations and enhance its competitive position against rival Eli Lilly.

The team, referred to internally as cardiometabolic educators, was a significant part of Novo Nordisk's commercial division and comprised several hundred employees. The layoffs reflect a broader trend within the pharmaceutical industry as companies grapple with rising costs and seek to optimize their resources.

As the market for obesity medications continues to evolve, Novo Nordisk's decision to reduce its workforce in this area signals a shift in focus that may impact its outreach and educational initiatives aimed at healthcare professionals. Observers will be watching closely to see how this decision affects the company's market performance and its ability to compete effectively in the obesity treatment sector.